𝛼SK or Searchbullish
Imugene Ltd - BTKi cohort builds with 71% overall response rate
SUMMARY
- Imugene Ltd (ASX:IMU) is a clinical-stage immuno-oncology company that has transitioned from a wide-ranging pipeline into a highly-focused vehicle concentrating on CAR-T.
- It is currently developing its platform azer-cel, an allogeneic ‘off-the-shelf’ CD19 CAR-T cell therapy for blood cancers.
- IMU announced on 5 October 2026 that its BTKi Combination Cohort (Cohort 3) continues to progress with four additional patients evaluated at Day 28, with one Complete Response (CR) in Mantle Cell Lymphoma (MCL) and one Partial Response (PR) in Chronic Lymphocytic Leukemia (CLL).
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Imugene Ltd - BTKi cohort builds with 71% overall response rate07 Oct 2026
x